Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Trial Type:  Treatment
Treatment/Intervention:  adoptive immunotherapy
Results 1-25 of 157 for your search:
Start Over
Clofarabine and Cytarabine or Standard Induction Therapy and Chemotherapy with or without Natural Killer Cell Transplant in Treating Younger Patients with Newly Diagnosed Acute Myeloid Leukemia
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and under
Trial IDs: AML08, NCI-2011-03659, NCT00703820
TK008: Efficacy Study on the Strategy of Herpes Simplex Virus Thymidine Kinase (HSV-Tk) Donor Lymphocytes to Treat Patients With High Risk Acute Leukemia
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: TK008, NCI-2011-03649, 2009-012973-37, NCT00914628
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CL-CA-P01, NCI-2015-00099, 2014-000544-15, 2015-001984-38, CL-CA-P01-00-US, NCT01875653
Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients with Relapsed or Refractory Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Age: 65 and under
Trial IDs: 1409.00, NCI-2010-00130, FHCRC-1409.00, 4903, NCI-G00-1776, NCT00005803
Alemtuzumab Before Donor Stem Cell Transplant in Treating Patients With Hematologic Diseases
Phase: Phase II, Phase I
Type: Treatment
Age: 70 and under
Trial IDs: HIMSUM, NCI-2012-00639, NCT00058825
Busulfan, Fludarabine Phosphate, Total-Body Irradiation, and Donor Stem Cell Transplant in Treating Patients with Hematologic Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 75
Trial IDs: HEM-05011-L, NCI-2013-00779, CDR0000447204, OHSU-210, OHSU-HEM-05011-L, NCT00245037
Reduced Intensity Donor Stem Cell Transplant With Natural Killer Cell Infusion in Treating Younger Patients with Recurrent or Refractory Acute Leukemia or Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 25 and under
Trial IDs: BMT06407, NCI-2011-00687, 2006-0297, 2012-0661, NCT00582816
Multi-Virus-Specific Donor T Cells in Treating Patients With B Cell Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, or Non-Hodgkin Lymphoma Who Have Undergone Donor Stem Cell Transplant
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 80 and under
Trial IDs: MULTIPRAT, NCI-2012-00636, 23637-MULTIPRAT, H-23637, NCT00840853
Vaccine Therapy and/or Glycosylated Recombinant Human Interleukin-7 after Standard Therapy in Treating Younger Patients with High Risk Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 19 months to 35 years
Trial IDs: 07-C-0206, NCI-2013-01440, 070206, 339168, NCT00526240, P6941, NCT00923351
Autologous or Donor Cytotoxic T-Lymphocytes in Treating Patients with Epstein-Barr Virus-Positive Hematologic Malignancy
Phase: Phase II, Phase I
Type: Treatment
Age: Any age
Trial IDs: ALCI, NCI-2012-00653, 9936-ALCI, H-9936, NCT00070226, NCT00671164, NCT00062868
Genetically Modified T Cells, Aldesleukin, and Combination Chemotherapy in Treating Patients with Metastatic Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 11-C-0013, NCI-2013-01468, 1004-1036, 110013, 344344, P10648, RD-10-IV-02, NCT01218867
Laboratory-Treated T-cells in Treating Patients with Relapsed Multiple Myeloma Undergoing Stem Cell Transplant
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 75
Trial IDs: 11-C-0016, NCI-2013-01469, 110016, FWA- 00000331, NIH 2514-1, NIH 2514-2, P08470, NCT01239368
Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ADP 01611, NCI-2014-01584, UPCC 01611, NCT01350401
Laboratory-Treated Therapeutic Autologous Lymphocytes in Treating Patients With Advanced Multiple Myeloma Undergoing Stem Cell Transplant
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 80
Trial IDs: UPCC 01411, NCI-2011-00960, NCT01352286
Recombinant Interleukin-15 After Chemotherapy and Tumor Infiltrating Lymphocyte Transfer in Treating Patients With Metastatic Melanoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-C-0170, NCI-2013-01492, P10798, NCT01369888
Genetically Modified T Cells in Treating Patients with Malignant Gliomas
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 11-C-0266, NCI-2013-01508, 110266, 1103-1095, P11810, RD-11-III-06, NCT01454596
CNDO-109-AANK for AML in First Complete Remission (CR1)
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CNDO109-001, NCI-2012-01374, NCT01520558
CT Antigen TCR-redirected T Cells for Ovarian Cancer.
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ADP-0011-001, NCI-2015-00728, 230612, NCT01567891
Genetically Engineered Lymphocytes in Treating Patients with Metastatic Cancer or Cancer That Cannot Be Removed by Surgery Receiving Chemotherapy and Aldesleukin
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 66
Trial IDs: 12-C-0111, NCI-2013-01516, 1112-1139, 120111, P11928, RD-12-I-02, NCT01583686
Laboratory-Treated T Cells in Treating Patients with High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated with Donor Stem Cell Transplant
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: 2498.00, NCI-2011-03362, NCT01640301
Conventional and Regulatory T Cells in Treating Patients With Advanced Hematologic Malignancies Undergoing T Cell-Depleted Donor Stem Cell Transplant
Phase: Phase II, Phase I
Type: Treatment
Age: 13 to 60
Trial IDs: BMT236, NCI-2011-03025, NCT01660607
Multivirus-Specific T Cells in Preventing or Treating Epstein-Barr Virus, Cytomegalovirus, or Adenovirus Infection After Donor Stem Cell Transplant
Phase: Phase II, Phase I
Type: Treatment
Age: Not specified
Trial IDs: VIRAGE, NCI-2012-00765, H-26374, NCT01070797
Umbilical Cord Blood-Derived Natural Killer Cells, Lenalidomide, High-Dose Melphalan, and Stem Cell Transplant in Treating Patients with Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 75
Trial IDs: 2011-0379, NCI-2014-01096, NCT01729091
Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients with Stage III or Metastatic Melanoma
Phase: Phase II, Phase I
Type: Treatment
Age: 14 and over
Trial IDs: 2009-0471, NCI-2014-02655, NCT01740557
Start Over